Riociguat (Standard)
Riociguat (Standard) is the analytical standard of Riociguat. This product is intended for research and analytical applications. Riociguat is an oral stimulator of soluble guanylate cyclase (sGC) used in the treatment of pulmonary hypertension.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 98%
- CAS No.: 625115-55-1
- Formule: C20H19FN8O2
- Masse moléculaire:422.42
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Product Information
-
Chemical Information
- Pureté et documentation
-
Help & FAQs
-
HY-14779
Riociguat -
HY-16774
VericiguatsCG Stimulator -
HY-14181
CinaciguatGuanylate Cyclase Activator -
HY-17584
LinaclotideGuanylate Cyclase Agonist -
HY-12376
BAY 41-2272Guanylate Cyclase Activator -
HY-W013386
LY83583sGC Inhibitor -
HY-14927
LificiguatsGC Activator -
HY-W062836
BAY 41-8543sGC Stimulator -
HY-78237
NelociguatGuanylate Cyclase Activator -
HY-16774R
Vericiguat (Standard)sCG Stimulator -
HY-14181A
Cinaciguat hydrochlorideGuanylate Cyclase Activator -
HY-12379
NS-2028Guanylyl Cyclase
Product Information
Information
Application
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
Chemical Information
-
CAS No. 625115-55-1
-
Masse moléculaire 422.42
-
Formule C20H19FN8O2
-
SMILES
FC1=CC=CC=C1CN2C3=NC=CC=C3C(C4=NC(N)=C(C(N)=N4)N(C)C(OC)=O)=N2
-
Synonyms
BAY 632521 (Standard)
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
[1]. Schermuly RT, et al. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur Respir J. 2008 Oct;32(4):881-91. [Content Brief]
[2]. Schermuly RT, et al. Riociguat for the treatment of pulmonary hypertension. Expert Opin Investig Drugs. 2011 Apr;20(4):567-76. [Content Brief]
[3]. Donda K, et al. Riociguat prevents hyperoxia-induced lung injury and pulmonary hypertension in neonatal rats without effects on long bone growth. PLoS One. 2018 Jul 10;13(7):e0199927. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Riociguat (Standard) Related Classifications
HY-14779R Related Classifications
Powered by Bioz